The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

When "no data" is the complete and final answer

This is a generated summary. It shows the 9 most-liked posts from a topic of 166, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
SP
s.poulsenTL3Regular Solution15 Oct 2024#4
n.torrence, post #2: Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive. Go to post

On post #2 — agreed on the reasoning, with one qualification.

Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.

8 likes in reply to #2 21mo
RN
r.novakTL2 Moderator3 Nov 2024#14
k.adeyemi, post #12: post #11 answers the question as asked. The question underneath it is different. Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is… Go to post

AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.

30 likes in reply to #12 21mo
MD
methods_draftTL2Member11 Nov 2024#19

This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits applies to everything discussed, not just to approved drugs.

29 likes 20mo
CC
c.correiaTL2 Moderator30 Nov 2024#31

Coming back to post #29, because the follow-up matters more than the original answer.

Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages.

31 likes 20mo
RM
r.mensahTL2 Moderator30 Jan 2025#79

How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.

32 likes 18mo
NR
n.rowntreeTL3Regular2 Feb 2025#82

Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages.

32 likes 18mo
N
NorringtonTL3Regular10 Mar 2025#114

Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.

32 likes 17mo
JI
j.iyerTL2 Moderator28 Mar 2025#131
e.roos, post #73: Compounds this community declines to help with, and why: there are specifics in the guidelines and they are not arbitrary. They exist because of failure modes that have happened in real people, not because of prudishness. Go to post

Picking up post #128: that is the part I would want checked first.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

30 likes in reply to #73 16mo
AL
aliquot_lineTL3Regular13 Apr 2025#147

Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.

33 likes 15mo

Read the full topic (166 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Sequence verification for an obscure compound: how it is done — what changed since
On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please…
TNDBSOLGHF+100 108 1.3k 8mo
Naming conventions for research peptides and the confusion they cause
Posting this under the heading it deserves: Naming conventions for research peptides and the confusion they cause Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with STEP 1 ( N…
ATNFPNDA+21 25 4.9k 22d
Why catalogue breadth is not evidence of anything — what changed since
Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
NEHFDBBKLG+62 66 26k 10mo
Compounds this community declines to help with, and why — does this still hold?
Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med ,…
TGAVGDAT+3 7 26k 7h
Compounds this community declines to help with, and why
Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SCALE ( N Engl J Med , 2015) and…
MKJSMSRFF+81 87 35k 10mo

Related topics — sharing the tags custom synthesis, mislabelling, needs a source

TopicParticipantsRepliesViewsActivity
Follow-up: Oral contraceptives and delayed emptying: what the data shows
Oral contraceptives and delayed emptying: what the data shows — setting out what I have, and where I think it stops being reliable. Reporting something rather than asking about it, in case the pattern is…
KMPEHBMSRL+31 35 13k 18mo
Reading an interaction checker output critically
On the subject in the title: Reading an interaction checker output critically Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking rather than…
RMASKBSFPF+144 152 3k 4mo
Reading a regulatory notice rather than an article about it — what changed since
Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually…
NSJRIBTYCC+28 32 640 13mo
Revisiting: What a well-designed human trial of a secretagogue would look like
On the subject in the title: Revisiting: What a well-designed human trial of a secretagogue would look like Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it…
HBSBOIDAS+69 74 25k 18mo
Second pass at: Why this subcategory is stricter about sourcing than most
Second pass at: Why this subcategory is stricter about sourcing than most — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SURMOUNT-4 ( JAMA ,…
AWGHTVCDAS+120 129 61k 11mo